CompuGroup Medical SE & Co. KGaA

  • WKN: A28890
  • ISIN: DE000A288904
  • Land: Deutschland

Nachricht vom 25.11.2021 | 20:56

CompuGroup Medical SE & Co. KGaA adopts resolution on share buy-back program for up to 500,000 treasury shares

CompuGroup Medical SE & Co. KGaA / Key word(s): Share Buyback
CompuGroup Medical SE & Co. KGaA adopts resolution on share buy-back program for up to 500,000 treasury shares

25-Nov-2021 / 20:56 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


The general partner of CompuGroup Medical SE & Co. KGaA (the "Company") (ISIN: DE000A288904 | WKN: A28890), utilising the authorization granted by its annual general meeting of May 19, 2021 and pursuant to section 71(1) no. 8 of the German Stock Corporation Act (Aktiengesetz), resolved today to buy back a maximum number of up to 500,000 shares of the Company (corresponding to approx. 0.93% of the Company's share capital) at a maximum purchase price (excluding transaction costs) of up to EUR 37,000,000.00 in total (the "Share Buy-back Program").

The Share Buy-back Program will be carried out by a credit institution. The credit institution will acquire the shares on the stock market and will decide on the timing of acquisition independently of the Company in accordance with the safe harbor provisions of Article 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 (Market Abuse Regulation) in conjunction with the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016. In addition, the consideration paid per share (excluding transaction costs) must not exceed, or fall short of, the price of the Company's shares in XETRA (or a comparable successor system) trading on the Frankfurt Stock Exchange determined by the opening auction on the trading day by more than 10%.

Shares will be bought back in the period from November 26, 2021 to and including January 27, 2022. The Company's treasury shares acquired by means of the Share Buy-back Program may be used for any purpose permitted under the authorization granted by the annual general meeting of May 19, 2021.

Further details will be published separately by the Company prior to the start of the share buy-back.


25-Nov-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021